<DOC>
	<DOCNO>NCT02799199</DOCNO>
	<brief_summary>Objectives : This study describe efficacy safety Fingolimod patient treat least 6 month east France January 2011 December 2014 . Background : The Grand-Est geographical region France high prevalence multiple sclerosis ( 10000 patient registered European Database Multiple Sclerosis ( EDMUS ) database ) . In region since January 2011 , 1014 patient treat least 6 month Fingolimod , first oral therapy patient active relapsing-remitting MS. Methods : Features patient follow Grand-Est region treat fingolimod 6 university hospital , general hospital private neurologist review retrospective study identification clinical file report EDMUS database .</brief_summary>
	<brief_title>Fingolimod Real World Experience : French Grand-Est Cohort</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Patients MS treat Gilenya disease contraindication Gilenya treatment receive Gilenya 31st March 2014</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>